Aliou Traoré

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet · 2018 · 142 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +16

Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study

Khalid B. Beshir, Julian Muwanguzi, Johanna Nader et al. · The Lancet Infectious Diseases · 2022 · 68 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17

Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali

Hamma Maiga, Estrella Lasry, Modibo Diarra et al. · PLoS ONE · 2016 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy of artesunate–amodiaquine, dihydroartemisinin–piperaquine and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger

Francesco Grandesso, Ousmane Guindo, Lynda Woi Messe et al. · Malaria Journal · 2018 · 39 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of three years’ seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali

Almahamoudou Mahamar, Kelsey M. Sumner, Brandt Levitt et al. · Malaria Journal · 2022 · 33 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacology +17